Pharma and Biopharma Outsourcing Solutions from Intertek - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharma and Biopharma Outsourcing Solutions from Intertek

Intertek, a leading provider of Pharmaceutical Services will highlight how its unique blend of expert pharmaceutical & biopharmaceutical analysis, auditing and regulatory services are helping to save the industry material costs whilst raising the safety of its products and reliability of its supply chains at ICSE / CPhi, Madrid, Spain, 9-11 October 2012. Stand 10E89.

In particular Intertek’s service offering for biologics will be a key focus area. With the annual sales of biologic drugs forecast to grow up to three times faster than conventional drugs over the next 5 years Intertek’s strategy has been to establish a “one stop” analytical shop specifically relating to the requirements of ICH Q6B. The team, based in UK, Ireland, Basel and Sand Diego specializes in the design and delivery of regulatory (GXP) studies relating to the physiochemical and biological activity of biomolecules, bioanalytical support and manufacturing troubleshooting.

Experts from Intertek Pharmaceutical Services will be available during ICSE to share the experience of its history of successful innovative and tailored programmes. Covering a wide scope of services for both clinical development and product testing, such as GLP bioanalysis, GMP product analysis, auditing, method development validation and remediation, GMP microbiology, manufacturing technical support or sustainability consultancy, Intertek experts will be engaging on clients’ outsourcing needs for the year ahead and beyond.

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
FindPharma Custom Search

Click here